Pharmaceutical, Healthcare B2B investment conference begins from 17th
ISLAMABAD: Pakistan is all set to host a two-day Pharmaceutical and Healthcare business-to-business (B2B)investment conference in Islamabad from 17-18 July aimed at promoting investment and industrial cooperation in the pharmaceutical, healthcare, and biotechnology sectors.
This was stated by Federal Minister for National Health Services and Regulations, Syed Mustafa Kamal, while addressing a joint press conference, along with Federal Minister for Board of Investment, Qaiser Ahmed Sheikh, and Special Assistant to the Prime Minister (SAPM) for Industries and Production, Haroon Akhtar Khan, here on Wednesday.
Kamal said that this conference is conceived as a premium business facilitation initiative, which is organized and facilitated by the Health Ministry, the Drug Regulatory Authority of Pakistan (DRAP), the Trade Development Authority of Pakistan (TDAP), and the Board of Investment (BOI) Pakistan, with critical diplomatic coordination provided by the Embassy of Pakistan in Beijing.
The conference is aimed at deepening bilateral collaboration by encouraging investment, technology transfer, and industrial partnerships in the pharmaceutical and healthcare industries. The conference will include B2Bmeetings, networking opportunities, and dedicated investment sessions to facilitate engagement between companies from both countries.
The conference is also expected to support the modernization of Pakistan’s healthcare system while improving the competitiveness of the country’s pharmaceutical industry. Backed by the SIFC, Pakistan’s healthcare and pharmaceutical sectors continue to present new opportunities for advanced technology, investment, and industrial collaboration.
He said that this significant event did not happen overnight; it is the culmination of two months of intense diplomatic and technical groundwork. Teams from the Ministry and DRAP worked day and night alongside the Pakistan Embassy in Beijing to meticulously analyze both markets, mapping the exact structural gaps where Pakistan requires localized manufacturing and where China holds global expertise.
This intensive preparatory exercise successfully brought more than 450 pre-mapped companies to the table, gathering a powerful assembly of over 300 leading Pakistani firms and 150 elite Chinese industrial groups, to move decisively past general trade shows toward a high-value industrial alliance based on commercially viable joint ventures, contract manufacturing setups, and deep technology transfers.
The bilateral engagements are systematically structured around seven high-potential priority investment sectors backed by comprehensive, data-driven investment pitch books: Active Pharmaceutical Ingredients (APIs): Reducing reliance on imported raw materials to achieve upstream self-sufficiency. Biotechnology Products and Vaccines (Human and Veterinary): Partnering with advanced Chinese biotech firms for localized production, leveraging Pakistan’s newly approved National Vaccine Policy. Medical Devices and Advanced Medical Technology: Upgrading domestic manufacturing from basic consumables to complex, high-value medical hardware and diagnostic systems.
Generic Formulations: High-end specialized manufacturing including Injectables and Oral Solid Dosages (OSDs).
Clinical Trials and Research: Capitalizing on regional clinical pathways and research standards. Traditional, Herbal, and Nutraceutical Medicines: Exploring natural product industrialization using modern scientific standards.
Reflecting the intense preparation of the past months, the opening morning will culminate immediately in an Exchange of Official Agreements and Partnership Signing for indigenous manufacturing before moving into the first of three highly anticipated, structured B2B matchmaking sessions.
To maximize investment velocity, the organizing institutions have embedded an extensive support infrastructure directly within the venue. Live, dedicated Information and Facilitation Desks staffed by top officials from DRAP, BOI, and the Special Investment Facilitation Council (SIFC) will sit directly in the room to assess and clear regulatory inquiries, joint venture structures, and legal frameworks in real-time.
Recognizing that regulatory alignment is the cornerstone of sustainable investment, the second day begins with a comprehensive technical session led by DRAP. Senior regulatory experts will outline Pakistan’s modernized regulatory landscape, showcasing its end-to-end digitized licensing and registration portals and its seamless integration with the Pakistan Single Window (PSW) for frictionless trade clearance. The remainder of Day 2 features deep-dive B2B matchmaking sessions dedicated to finalizing commercial agreements, defining operational timelines, and executing subsequent Memoranda of Understanding (MoUs) with immediate, binding execution timelines.
To maximize investment velocity, the organizing institutions have embedded an extensive support infrastructure directly within the venue.
Dedicated Information and Facilitation Desks staffed by active representatives from DRAP, Ministry of NHSR&C, BOI, and the Special Investment Facilitation Council (SIFC) will provide real-time guidance on regulatory pathways, licensing, and investment incentives.
Furthermore, the venue will feature reserved bilateral meeting rooms, specialized MoU facilitation teams, and professional interpretation services to ensure seamless, barrier-free communication between Pakistani and Chinese executives.
Copyright Business Recorder, 2026